Semantic Coherence: Kyowa Kirin Co., Ltd. – Signal Evidence & AI Readability

Delivering Life-changing valueas a Global Specialty Pharmaceutical companyCorporate video

Welcome to Kyowa Kirin Global Corporate WebsiteGo to your country or region website

Pursue advances in life sciences and technologiesDriven by state-of-art antibody technologies and hematopoietic stem cell gene therapy,in the core therapeutic areas of bone & mineral, intractable hematologicaldiseases/hemato oncology, and rare disease.
See what we do

Integrated Report 2024We strive to contribute to the health and well-being of people aroundthe world by creating new value through the pursuit ofadvances in life sciences and technologies.See more
[IMG: Open in new window]

[H2] Notice

February 24, 2023Kyowa Kirin’s Humanitarian Donation for Earthquake Relief in Turkey and Syria
[IMG: PDF file]

October 21, 2022Please be careful of e-mails that misrepresent Kyowa Kirin
[IMG: PDF file]

See more

[H2] News Releases

See more

[H2] Stories

[H3] Inside the Innovation Center’s Research Environment: Advancing Early-Stage Drug Discovery (Part 1)

Innovation | April 1, 2026

[H3] Inside the Innovation Center’s Research Environment: How New Ideas Emerge and Teams Are Managed (Part 2)

Innovation | April 1, 2026

[H3] Julie Dehaene-Puype Message for International Women's Day

People & Culture | March 12, 2026

[H3] Transforming Rare Disease Care: Orchard Therapeutics and the Future of Gene Therapy

Growth | March 10, 2026

[H3] CEO and COO Message on Rare Disease Day 2026

Patients | February 2, 2026

[H3] COO × CPO Discussion: Behind the Formulation of Our KABEGOE Principles Shaping Kyowa Kirin’s Corporate Culture

People & Culture | January 26, 2026

See more

[H2] In numbers

[IMG: 2 gene therapies in pipeline]

[IMG: 6 antibody drugs in pipeline]

[IMG: 18 development programs]

[IMG: over 50 markets reach worldwide]

[IMG: 72% overseas sales]

[IMG: 41 group companies]

[IMG: core operating profit 95 billion yen]

[IMG: annual revenue 496 billion yen]

[IMG: 5,669 employees]

[IMG: over 70-year heritage]

[IMG: 2 gene therapies in pipeline]

[IMG: 6 antibody drugs in pipeline]

[IMG: 18 development programs]

[IMG: over 50 markets reach worldwide]

[IMG: 72% overseas sales]

[IMG: 41 group companies]

[IMG: core operating profit 95 billion yen]

[IMG: annual revenue 496 billion yen]

[IMG: 5,669 employees]

[IMG: over 70-year heritage]

click to close window

pause

[H2] Our philosophy

The Kyowa Kirin Group companies strive tocontribute to the health and well-being of people aroundthe world by creating new value through the pursuit ofadvances in life sciences and technologies.

[H2] Core values

Our goal is clear: to do everything we can to answer theunmet medical needs of patients, their families, and medical professionals, and to do it as quickly as possible.Because every moment counts.
Our values are a way of thinking and attitudethat supports the activity of each officer andemployee belonging to the Kyowa KirinGroup. It consists of core concept"Commitment to Life" and three key words.

[IMG: Commitment to Life For us, innovation does not just mean growth. It means doing everything we can to improve the quality of life for people around the world. READ THE FULL MISSION STATEMENT show content]

[IMG: Commitment to Life For us, innovation does not just mean growth. It means doing everything we can to improve the quality of life for people around the world. READ THE FULL MISSION STATEMENT show content]

[IMG: Innovation show content]

[IMG: Innovation Transform lives with passion and excitement. Challenge the status quo in all of our work. close content]

[IMG: Innovation Transform lives with passion and excitement. Challenge the status quo in all of our work.]

[IMG: Integrity show content]

[IMG: Integrity Do the right things. Be sincere and ethical consistently Make a better world through good business practices. close content]

[IMG: Integrity Do the right things. Be sincere and ethical consistently. Make a better world through good business practices.]

[IMG: Teamwork/Wa show content]

[IMG: Teamwork/Wa One for all, all for one. Work in diverse teams and respect each other. Go beyond boundaries and collaborate with stakeholders. close content]

[IMG: Teamwork/Wa One for all, all for one. Work in diverse teams and respect each other. Go beyond boundaries and collaborate with stakeholders.]

close

Countless precious lives surround us.
Brought into this world, blessed, raised with loving care - full of dreams, happiness as the goal of life.
Deeply instill in us, and know that what we work for - the most precious presence of all on this planet.
Infinite possibilities for us, a pharmaceutical company.

Believe in ourselves, believe in our power, believe in what we have built together.
Not a large company, but with qualities like none other.
History so unique we can be proud of technology unmatched,
And superior human beings that cannot be found elsewhere.

Be brave; do not shy away from challenges.
Have passion; break away from the norm.
Innovation is not just about growth - but instead a leap towards the future, a grand growth with wings.
Wings never to be given to those who settle for the status-quo.

Don't just make medicine. Make people smile, bring light to their lives.
How strongly one longs to live. How deeply one is loved by their loved ones.
How sincerely one desires to help the one life they dedicate themselves to in the field of medicine.
Stay receptive, sharpen your sensitivities.
Let us become the top company in the world who cares the most for life.
Strength is not what saves the world. A caring heart is what the world calls for.

Strive to become a superb team.
One human being, excellent or not, is ever so powerless, as a power of one, mistakes, even a possibility.
Show the world the excellence of coming together. Amazing results, when we become one.
Be driven. Think of those fighting for their lives every day.
Their strong devotion to life speaks to our hearts.
Hurry - do not scurry, but we must not stand still. Stay sincere, always - may that be our vow.
We make medicine. This is, our walk of life.

Work, can bring happiness. Remember this, always.
Born on this planet in various parts of the globe, passing through life in different ways,
And like a miracle we found one another - our jobs, our team, our company.
Know this, and be fulfilled, always.
Be thankful of what you have, pour your heart and soul into the mission you were given,
Be proud of your work, the work to save precious lives.

We are, each and everyone of us, Kyowa Kirin.

Taking the walk of life,
one life at a time.

close

[H2] At a glance

Find out more about our company and our commitment
to making positive contributions in human health andcommunity welfare.

Managementopen

Productsmove to page

Research & Developmentmove to page

Governancemove to page

Historymove to page

Overviewmove to page

[IMG: KYOWA KIRIN]

Sustainabilitymove to page

Storiesof life-changingvalue creation and deliverymove to page

Corporate videomove to page

close
Our Leadership

[IMG: For the creation and delivery of life-changing value that ultimately makes people smile Masashi Miyamoto Representative Director, Chairman of the Board Abdul Mullick Representative Director, President & CEO]

Leadership Message

Kyowa Kirin upholds the management philosophy of "contributing to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies." As a Japan-based global specialty pharmaceutical company, we are dedicated to utilizing diverse drug discovery technologies, including our unique antibody technologies, to develop groundbreaking new drugs that bring smiles to people's faces.

Our vision for 2030 is to "realize the successful creation and delivery of life-changing value that ultimately makes people smile, as a Japan-based global specialty pharmaceutical company built on a diverse team of experts with a shared passion for innovation."

To achieve this vision, we have defined our focus areas based on the "Story for Vision 2030." These areas include bone and mineral diseases, hematologic malignancies and refractory hematologic diseases, and rare diseases. We are advancing our proprietary antibody technologies and applying modalities like hematopoietic stem cell gene therapy (HSC-GT), while promoting open innovation and partnerships. By identifying unmet medical needs and creating and delivering new drugs and services to meet those needs, and by fostering innovation with patients, we aim to continue creating life-changing value that makes people smile.

And to achieve this, we should first and foremost bring smiles to our employees. In a passage from "Commitment to Life" created at the time of our establishment in 2008, there is a phrase that states, "Not a large company, but with qualities like none other" In other words, the underlying value is not about the size of the company but rather about "making a difference." To invest in our employees’ career growth, development, and overall wellbeing, I believe that their smiles will bring to smiles for those facing illnesses.

Moving forward, we will continue to work as one Kyowa Kirin team to contribute to the health and well-being of people around the world.

Masashi Miyamoto
Representative Director, Chairman of the Board

Abdul Mullick
Representative Director, President and CEO

close
Our Leadership

[H2] Global network

Kyowa Kirin Group companies are dedicated toimproving quality of life by answering the unmet medicalneeds of people worldwide.

[H3] Kyowa Kirin Co., Ltd.JAPAC (Japan & Asia Pacific)

[H3] Kyowa Kirin International plc.UK - EMEA

[H3] Kyowa Kirin USA Holdings, Inc.USA - NORTH AMERICA

[H3] Orchard Therapeutics plcUK - EMEAUSA - NORTH AMERICA

[H4] Kyowa Kirin Co., Ltd.JAPAC (Japan & Asia Pacific)

Visit the website(日本語)
[IMG: Open in new window]

Subsidiaries in Japan & Asia Pacific:
Kyowa Kirin plus Co., Ltd.(日本語
[IMG: Open in new window]
)
FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
(日本語
[IMG: Open in new window]
/ English
[IMG: Open in new window]
)
Kyowa Kirin Frontier Co., Ltd.(日本語
[IMG: Open in new window]
)
Cowellnex Co., Ltd.(日本語
[IMG: Open in new window]
/ English
[IMG: Open in new window]
)
Kyowa Kirin Korea Co., Ltd.
(Korea: 한국어
[IMG: Open in new window]
)
Kyowa Kirin Taiwan Co., Ltd.
(Taiwan: 中文
[IMG: Open in new window]
)
Kyowa Kirin Australia Pty Ltd.(English
[IMG: Open in new window]
)

[H4] Kyowa Kirin International plc.UK - EMEA

Visit the website
[IMG: Open in new window]

Subsidiaries in EMEA:
Kyowa Kirin Ltd. (UK: English
[IMG: Open in new window]
)
Kyowa Kirin Pharma SAS (français)
Kyowa Kirin Farmaceutica, S.L.U. (Spain: Español
[IMG: Open in new window]
)
Kyowa Kirin GmbH (Germany: Deutsch
[IMG: Open in new window]
)
Kyowa Kirin Pharma B.V. (Netherlands: Nederlands
[IMG: Open in new window]
)
Kyowa Kirin Pharma B.V.
(Belgium + Luxembourg: English
[IMG: Open in new window]
)
Kyowa Kirin S.r.l. (Italy: Italiano
[IMG: Open in new window]
)
Kyowa Kirin AB (Sweden: Svenska
[IMG: Open in new window]
)
Kyowa Kirin AB (Norway: English
[IMG: Open in new window]
)
Kyowa Kirin AB (Finland: English
[IMG: Open in new window]
)
Kyowa Kirin AB (Denmark: English
[IMG: Open in new window]
)

[H4] Kyowa Kirin USA Holdings, Inc.USA - NORTH AMERICA

Visit the website(English)
[IMG: Open in new window]

Subsidiaries in North America:
BioWa, Inc. (USA: English
[IMG: Open in new window]
)
Kyowa Kirin, Inc. (USA: English
[IMG: Open in new window]
)

[H4] Orchard Therapeutics plcUK - EMEAUSA - NORTH AMERICA

Subsidiaries in EMEA & NORTH AMERICA:
UK Office (London
[IMG: Open in new window]
)
US Office (Boston
[IMG: Open in new window]
)

[H2] Careers

Our best results come from our people. As a Japan-based global specialty pharmaceutical company,Kyowa Kirin will continue to contribute to the health andwellbeing of people around the world.

LEARN MORE

The Story of Basic Immunology

Delivering Life-changing valueas a Global Specialty Pharmaceutical companyCorporate video

Welcome to Kyowa Kirin Global Corporate WebsiteGo to your country or region website

Pursue advances in life sciences and technologiesDriven by state-of-art antibody technologies and hematopoietic stem cell gene therapy,in the core therapeutic areas of bone & mineral, intractable hematologicaldiseases/hemato oncology, and rare disease.
See what we do

Integrated Report 2024We strive to contribute to the health and well-being of people aroundthe world by creating new value through the pursuit ofadvances in life sciences and technologies.See more
[IMG: Open in new window]

[H2] Notice

February 24, 2023Kyowa Kirin’s Humanitarian Donation for Earthquake Relief in Turkey and Syria
[IMG: PDF file]

October 21, 2022Please be careful of e-mails that misrepresent Kyowa Kirin
[IMG: PDF file]

See more

[H2] News Releases

See more

[H2] Stories

[H3] Inside the Innovation Center’s Research Environment: Advancing Early-Stage Drug Discovery (Part 1)

Innovation | April 1, 2026

[H3] Inside the Innovation Center’s Research Environment: How New Ideas Emerge and Teams Are Managed (Part 2)

Innovation | April 1, 2026

[H3] Julie Dehaene-Puype Message for International Women's Day

People & Culture | March 12, 2026

[H3] Transforming Rare Disease Care: Orchard Therapeutics and the Future of Gene Therapy

Growth | March 10, 2026

[H3] CEO and COO Message on Rare Disease Day 2026

Patients | February 2, 2026

[H3] COO × CPO Discussion: Behind the Formulation of Our KABEGOE Principles Shaping Kyowa Kirin’s Corporate Culture

People & Culture | January 26, 2026

See more

[H2] In numbers

[IMG: 2 gene therapies in pipeline]

[IMG: 6 antibody drugs in pipeline]

[IMG: 18 development programs]

[IMG: over 50 markets reach worldwide]

[IMG: 72% overseas sales]

[IMG: 41 group companies]

[IMG: core operating profit 95 billion yen]

[IMG: annual revenue 496 billion yen]

[IMG: 5,669 employees]

[IMG: over 70-year heritage]

[IMG: 2 gene therapies in pipeline]

[IMG: 6 antibody drugs in pipeline]

[IMG: 18 development programs]

[IMG: over 50 markets reach worldwide]

[IMG: 72% overseas sales]

[IMG: 41 group companies]

[IMG: core operating profit 95 billion yen]

[IMG: annual revenue 496 billion yen]

[IMG: 5,669 employees]

[IMG: over 70-year heritage]

click to close window

pause

[H2] Our philosophy

The Kyowa Kirin Group companies strive tocontribute to the health and well-being of people aroundthe world by creating new value through the pursuit ofadvances in life sciences and technologies.

[H2] Core values

Our goal is clear: to do everything we can to answer theunmet medical needs of patients, their families, and medical professionals, and to do it as quickly as possible.Because every moment counts.
Our values are a way of thinking and attitudethat supports the activity of each officer andemployee belonging to the Kyowa KirinGroup. It consists of core concept"Commitment to Life" and three key words.

[IMG: Commitment to Life For us, innovation does not just mean growth. It means doing everything we can to improve the quality of life for people around the world. READ THE FULL MISSION STATEMENT show content]

[IMG: Commitment to Life For us, innovation does not just mean growth. It means doing everything we can to improve the quality of life for people around the world. READ THE FULL MISSION STATEMENT show content]

[IMG: Innovation show content]

[IMG: Innovation Transform lives with passion and excitement. Challenge the status quo in all of our work. close content]

[IMG: Innovation Transform lives with passion and excitement. Challenge the status quo in all of our work.]

[IMG: Integrity show content]

[IMG: Integrity Do the right things. Be sincere and ethical consistently Make a better world through good business practices. close content]

[IMG: Integrity Do the right things. Be sincere and ethical consistently. Make a better world through good business practices.]

[IMG: Teamwork/Wa show content]

[IMG: Teamwork/Wa One for all, all for one. Work in diverse teams and respect each other. Go beyond boundaries and collaborate with stakeholders. close content]

[IMG: Teamwork/Wa One for all, all for one. Work in diverse teams and respect each other. Go beyond boundaries and collaborate with stakeholders.]

close

Countless precious lives surround us.
Brought into this world, blessed, raised with loving care - full of dreams, happiness as the goal of life.
Deeply instill in us, and know that what we work for - the most precious presence of all on this planet.
Infinite possibilities for us, a pharmaceutical company.

Believe in ourselves, believe in our power, believe in what we have built together.
Not a large company, but with qualities like none other.
History so unique we can be proud of technology unmatched,
And superior human beings that cannot be found elsewhere.

Be brave; do not shy away from challenges.
Have passion; break away from the norm.
Innovation is not just about growth - but instead a leap towards the future, a grand growth with wings.
Wings never to be given to those who settle for the status-quo.

Don't just make medicine. Make people smile, bring light to their lives.
How strongly one longs to live. How deeply one is loved by their loved ones.
How sincerely one desires to help the one life they dedicate themselves to in the field of medicine.
Stay receptive, sharpen your sensitivities.
Let us become the top company in the world who cares the most for life.
Strength is not what saves the world. A caring heart is what the world calls for.

Strive to become a superb team.
One human being, excellent or not, is ever so powerless, as a power of one, mistakes, even a possibility.
Show the world the excellence of coming together. Amazing results, when we become one.
Be driven. Think of those fighting for their lives every day.
Their strong devotion to life speaks to our hearts.
Hurry - do not scurry, but we must not stand still. Stay sincere, always - may that be our vow.
We make medicine. This is, our walk of life.

Work, can bring happiness. Remember this, always.
Born on this planet in various parts of the globe, passing through life in different ways,
And like a miracle we found one another - our jobs, our team, our company.
Know this, and be fulfilled, always.
Be thankful of what you have, pour your heart and soul into the mission you were given,
Be proud of your work, the work to save precious lives.

We are, each and everyone of us, Kyowa Kirin.

Taking the walk of life,
one life at a time.

close

[H2] At a glance

Find out more about our company and our commitment
to making positive contributions in human health andcommunity welfare.

Managementopen

Productsmove to page

Research & Developmentmove to page

Governancemove to page

Historymove to page

Overviewmove to page

[IMG: KYOWA KIRIN]

Sustainabilitymove to page

Storiesof life-changingvalue creation and deliverymove to page

Corporate videomove to page

close
Our Leadership

[IMG: For the creation and delivery of life-changing value that ultimately makes people smile Masashi Miyamoto Representative Director, Chairman of the Board Abdul Mullick Representative Director, President & CEO]

Leadership Message

Kyowa Kirin upholds the management philosophy of "contributing to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies." As a Japan-based global specialty pharmaceutical company, we are dedicated to utilizing diverse drug discovery technologies, including our unique antibody technologies, to develop groundbreaking new drugs that bring smiles to people's faces.

Our vision for 2030 is to "realize the successful creation and delivery of life-changing value that ultimately makes people smile, as a Japan-based global specialty pharmaceutical company built on a diverse team of experts with a shared passion for innovation."

To achieve this vision, we have defined our focus areas based on the "Story for Vision 2030." These areas include bone and mineral diseases, hematologic malignancies and refractory hematologic diseases, and rare diseases. We are advancing our proprietary antibody technologies and applying modalities like hematopoietic stem cell gene therapy (HSC-GT), while promoting open innovation and partnerships. By identifying unmet medical needs and creating and delivering new drugs and services to meet those needs, and by fostering innovation with patients, we aim to continue creating life-changing value that makes people smile.

And to achieve this, we should first and foremost bring smiles to our employees. In a passage from "Commitment to Life" created at the time of our establishment in 2008, there is a phrase that states, "Not a large company, but with qualities like none other" In other words, the underlying value is not about the size of the company but rather about "making a difference." To invest in our employees’ career growth, development, and overall wellbeing, I believe that their smiles will bring to smiles for those facing illnesses.

Moving forward, we will continue to work as one Kyowa Kirin team to contribute to the health and well-being of people around the world.

Masashi Miyamoto
Representative Director, Chairman of the Board

Abdul Mullick
Representative Director, President and CEO

close
Our Leadership

[H2] Global network

Kyowa Kirin Group companies are dedicated toimproving quality of life by answering the unmet medicalneeds of people worldwide.

[H3] Kyowa Kirin Co., Ltd.JAPAC (Japan & Asia Pacific)

[H3] Kyowa Kirin International plc.UK - EMEA

[H3] Kyowa Kirin USA Holdings, Inc.USA - NORTH AMERICA

[H3] Orchard Therapeutics plcUK - EMEAUSA - NORTH AMERICA

[H4] Kyowa Kirin Co., Ltd.JAPAC (Japan & Asia Pacific)

Visit the website(日本語)
[IMG: Open in new window]

Subsidiaries in Japan & Asia Pacific:
Kyowa Kirin plus Co., Ltd.(日本語
[IMG: Open in new window]
)
FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
(日本語
[IMG: Open in new window]
/ English
[IMG: Open in new window]
)
Kyowa Kirin Frontier Co., Ltd.(日本語
[IMG: Open in new window]
)
Cowellnex Co., Ltd.(日本語
[IMG: Open in new window]
/ English
[IMG: Open in new window]
)
Kyowa Kirin Korea Co., Ltd.
(Korea: 한국어
[IMG: Open in new window]
)
Kyowa Kirin Taiwan Co., Ltd.
(Taiwan: 中文
[IMG: Open in new window]
)
Kyowa Kirin Australia Pty Ltd.(English
[IMG: Open in new window]
)

[H4] Kyowa Kirin International plc.UK - EMEA

Visit the website
[IMG: Open in new window]

Subsidiaries in EMEA:
Kyowa Kirin Ltd. (UK: English
[IMG: Open in new window]
)
Kyowa Kirin Pharma SAS (français)
Kyowa Kirin Farmaceutica, S.L.U. (Spain: Español
[IMG: Open in new window]
)
Kyowa Kirin GmbH (Germany: Deutsch
[IMG: Open in new window]
)
Kyowa Kirin Pharma B.V. (Netherlands: Nederlands
[IMG: Open in new window]
)
Kyowa Kirin Pharma B.V.
(Belgium + Luxembourg: English
[IMG: Open in new window]
)
Kyowa Kirin S.r.l. (Italy: Italiano
[IMG: Open in new window]
)
Kyowa Kirin AB (Sweden: Svenska
[IMG: Open in new window]
)
Kyowa Kirin AB (Norway: English
[IMG: Open in new window]
)
Kyowa Kirin AB (Finland: English
[IMG: Open in new window]
)
Kyowa Kirin AB (Denmark: English
[IMG: Open in new window]
)

[H4] Kyowa Kirin USA Holdings, Inc.USA - NORTH AMERICA

Visit the website(English)
[IMG: Open in new window]

Subsidiaries in North America:
BioWa, Inc. (USA: English
[IMG: Open in new window]
)
Kyowa Kirin, Inc. (USA: English
[IMG: Open in new window]
)

[H4] Orchard Therapeutics plcUK - EMEAUSA - NORTH AMERICA

Subsidiaries in EMEA & NORTH AMERICA:
UK Office (London
[IMG: Open in new window]
)
US Office (Boston
[IMG: Open in new window]
)

[H2] Careers

Our best results come from our people. As a Japan-based global specialty pharmaceutical company,Kyowa Kirin will continue to contribute to the health andwellbeing of people around the world.

LEARN MORE

The Story of Basic Immunology

[H1] Stories

of life-changing value creation and delivery

HOME
Stories

Filter

Patients
Innovation
Sustainability
People & Culture
Growth

2026
2025
2024
2023
2022
2021
2020
2019

All Reset

[H3] Inside the Innovation Center’s Research Environment: Advancing Early-Stage Drug Discovery (Part 1)

Innovation | April 1, 2026

[H3] Inside the Innovation Center’s Research Environment: How New Ideas Emerge and Teams Are Managed (Part 2)

Innovation | April 1, 2026

[H3] Julie Dehaene-Puype Message for International Women's Day

People & Culture | March 12, 2026

[H3] Transforming Rare Disease Care: Orchard Therapeutics and the Future of Gene Therapy

Growth | March 10, 2026

[H3] CEO and COO Message on Rare Disease Day 2026

Patients | February 2, 2026

[H3] COO × CPO Discussion: Behind the Formulation of Our KABEGOE Principles Shaping Kyowa Kirin’s Corporate Culture

People & Culture | January 26, 2026

[H3] Kyowa Kirin President & COO Abdul Mullick New Year’s Greeting

Growth | January 7, 2026

[H3] Why Listening to Patients Voices: Lessons Learned as New Employees of a Pharmaceutical Company

Patients | December 19, 2025

[H3] Kyowa Kirin Participates as Part of Kirin Group in Tokyo Pride 2025

People & Culture | December 10, 2025

[H3] Accelerating Biopharmaceutical Development: A Report from the Commemorative Presentations on the New HB7 Building at the Takasaki Plant (Part 1)

Growth | November 12, 2025

[H3] Accelerating Biopharmaceutical Development: A Report from the Commemorative Presentations on the New HB7 Building at the Takasaki Plant (Part 2)

Patients | November 12, 2025

[H3] Kyowa Kirin Supports International Awareness Day

Patients | October 24, 2025

[H3] Rare Disease Day 2025: Spreading Awareness and Support Holding Events Worldwide

Patients | August 29, 2025

[H3] Enhancing Patient-Centric Activities in Japan region’s Medical Affairs Department (MA Department): A Seminar with Guest Speakers, Including a Patient

Patients | August 19, 2025

[H3] Special Dialogue between the CEO & COO: Together, Pioneering New Horizons

Growth | July 24, 2025

[H3] “Healthcare Café” Report ─ A Platform for Patient Dialogue: Thinking About Hematopoietic Stem Cell Transplantation (Part One)

Patients | July 23, 2025

[H3] “Healthcare Café” Report ─ A Platform for Patient Dialogue: Thinking About Hematopoietic Stem Cell Transplantation (Part Two)

Patients | July 23, 2025

[H3] Special Discussion: Story for Vision 2030

Growth | June 23, 2025

[H3] PRIDE MONTH Message from Abdul Mullick, President and COO

People & Culture | June 2, 2025

[H3] Listening to Patients’ Voice and Responding to Their Needs: Kyowa Kirin's Patient Engagement Activities

Patients | March 18, 2025

[H3] Kyowa Kirin CPO Itagaki’s message for International Women’s Day

People & Culture | March 7, 2025

[H3] What is the Kyowa Kirin Group’s health and productivity management initiative, Wellness Action 2025?

People & Culture | February 10, 2025

[H3] Rare Disease Day 2025 - More Than You Can Imagine

Patients | February 7, 2025

[H3] Kyowa Kirin CEO Miyamoto’s New Year Message: Accelerate Our Reforms with Determination for Delivering Life-changing Value to Patients

Growth | January 14, 2025

[H3] Kyowa Kirin Hosted Booth at Tokyo Rainbow Pride 2024 for a Second Year in a Row: Initiatives for Accelerating DE&I and the Ideal State a Company Should Strive to Be (Part One)

People & Culture | October 15, 2024

[H3] Kyowa Kirin Hosted Booth at Tokyo Rainbow Pride 2024 for a Second Year in a Row: Initiatives for Accelerating DE&I and the Ideal State a Company Should Strive to Be (Part Two)

People & Culture | October 15, 2024

[H3] Strengthening our training framework to tackle the biopharmaceutical engineer shortage

People & Culture | September 20, 2024

[H3] Highlighting Kyowa Kirin's initiatives across regions for PRIDE MONTH 2024

People & Culture | September 13, 2024

[H3] Bio Adventure: Kyowa Kirin’s works with local communities on project to foster future scientists

People & Culture | August 9, 2024

[H3] PRIDE MONTH Message from Jeremy Morgan, President, Kyowa Kirin International plc (EMEA region)

People & Culture | July 5, 2024

[H3] Kyowa Kirin launches the CTCL Global Care Collaborative’s Time to Act global consensus statement

Patients | May 13, 2024

[H3] Kyowa Kirin Global Corporate Planning Head Shoko Itagaki’s Message for International Women's Day

People & Culture | March 8, 2024

[H3] Kyowa Kirin CEO Miyamoto’s New Year Message

Growth | January 9, 2024

[H3] Kyowa Kirin Chief International Business Officer Abdul Mullick’s Message on UN’s International Day of Persons with Disabilities

Sustainability | December 1, 2023

[H3] Kyowa Kirin hosted a booth for the first time at the Tokyo Rainbow Pride 2023 [Our Diversity, Equity & Inclusion]

People & Culture | November 9, 2023

[H3] Our Stable Supply of High-quality Pharmaceuticals

Sustainability | September 20, 2023

[H3] Provide pharmaceuticals for unmet medical needs - A Conversation with Kyowa Kirin’s R&D Executives

Innovation | August 22, 2023
[IMG: PDF file]

[H3] Ensure a Thriving Global Environment for Future Generations

Sustainability | July 28, 2023

[H3] “Menstruation” and “fertility treatment” felt like taboo subjects in the workplace - Why be open about issues unique to women? PartⅡ

People & Culture | June 9, 2023

[H3] “Menstruation” and “fertility treatment” felt like taboo subjects in the workplace - Why be open about issues unique to women? PartⅠ

People & Culture | April 25, 2023

[H3] Kyowa Kirin CEO Miyamoto’s Message on Rare Disease Day

Patients | February 28, 2023

[H3] Promoting patient advocacy and nurturing patient-centric care: Interview with Kyowa Kirin North America

Patients | February 14, 2023

[H3] Celebrating another year of diverse initiatives around the world: RDD 2022 in EMEA

Patients | January 24, 2023

[H3] Celebrating another year of diverse initiatives around the world: RDD 2022 in North America

Patients | December 15, 2022

[H3] Celebrating another year of diverse initiatives around the world: RDD 2022 in Asia Pacific

Patients | November 21, 2022

[H3] Celebrating another year of diverse initiatives around the world: RDD 2022 in Japan

Patients | October 20, 2022

[H3] Providing high-quality pharmaceuticals to patients around the world

Sustainability | September 22, 2022

[H3] Striving to create life-changing “Only-one value” that brings smiles to patients

Innovation | July 25, 2022

[H3] Kyowa Kirin International: It's Time to Shine A Light on XLH

Patients | June 27, 2022

[H3] Kyowa Kirin CEO Miyamoto’s Message on Pride Month

People & Culture | June 9, 2022

[H3] Kyowa Kirin International Celebrates the UN’s International Day of Persons with Disabilities in EMEA

People & Culture | January 20, 2022

[H3] Kyowa Kirin International: Around the world challenge

People & Culture | December 17, 2021
[IMG: Open in new window]

[H3] Kyowa Kirin North America: Honoring The Caregiver, Everyday Heroes, During National Family Caregivers Month

Patients | November 19, 2021

[H3] Kyowa Kirin's Effort to Realize a Sustainable Society

Sustainability | October 11, 2021

[H3] Our Financial Strategy for Creating Life-changing Value

Growth | September 9, 2021

[H3] Changes in society caused by COVID-19 and the impact on Kyowa Kirin

Growth | August 19, 2021

[H3] Bio Adventure Hands-On Experience Sessions: Become a drug discovery researcher During Your Summer Break

Sustainability | July 27, 2021

[H3] AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS

News Release | June 1, 2021

[H3] MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting

News Release | May 20, 2021

[H3] White Paper on the unrecognized burden of XLH in adults in Europe

Patients | July 13, 2020

[H3] Empowering Children to Ask "Why?": Tohoku University Science Campus Hands-On Science Lessons (First Half)

People & Culture | March 5, 2020

[H3] Empowering Children to Ask "Why?": Tohoku University Science Campus Hands-On Science Lessons (Second Half)

People & Culture | March 5, 2020

[H3] “Delivering smiles with sports” Creating an inclusive society through table tennis

Sustainability | January 14, 2020

[H3] Bio Adventure*: Kyowa Kirin Invites Children to a Science Adventure

People & Culture | July 3, 2019

[H1] Our ImpactKyowa Kirin practices CSV management aimed at realizing improved
corporate value through the creation of both social and economic value.

[H2] Topics

2023/11/14
[H3] Kyowa Kirin’s Value Co-creation

[H3]

Failed to retrieve accurate information. Please try accessing again after some time.

List of Topic Articles

[H3] Related Materials

Integrated Report
[IMG: Open in new window]

Kyowa Kirin Sustainability Meeting
[IMG: Open in new window]

[H3] Latest News

July 31, 2025

Update Our Impact page

July 31, 2024

Update Our Impact page

[H2] Kyowa Kirin aimsto provideLife-changing value

Here, we elaborate on our concept of value creation.
Representative Director,Chairman of the BoardMasashi Miyamoto

[IMG: Materiality]

[IMG: Our Philosophy and Vision]

[IMG: Group Policies]

[H2] Materiality-related Activities

[H3] Topics for value creation

[H4] Provide pharmaceuticals for unmet medical needs

Creation of innovative drugs
Maximize product value
Pipeline enrichment

[H4] Address patient-centric healthcare needs

Access to medicine
Create healthcare solutions beyond medicine
[IMG: PDF file]

[H4] Reinforce human resources and structures that support the creation of Life-changing value

Talent portfolio

DE&I

Corporate culture
Digital transformation

[H3] Topics for value enhancement

[H4] Retain the trust of society

Quality assurance anda supply of products
Reducing environmental impact

[H4] Reinforce human resources and structures that support the creation of Life-changing value: Management Infrastructure

Corporate governance
[IMG: Open in new window]

Ethics and transparency
Reinforce risk management

Health andProductivityManagement

SocialContributionActivities

Co-creatingValue withStakeholders

ESG Dataand ExternalAssessments

Stories